These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21950746)

  • 21. Comparison of blood tests for liver fibrosis specific or not to NAFLD.
    Calès P; Lainé F; Boursier J; Deugnier Y; Moal V; Oberti F; Hunault G; Rousselet MC; Hubert I; Laafi J; Ducluzeaux PH; Lunel F
    J Hepatol; 2009 Jan; 50(1):165-73. PubMed ID: 18977552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
    Stibbe KJ; Verveer C; Francke J; Hansen BE; Zondervan PE; Kuipers EJ; de Knegt RJ; van Vuuren AJ
    Scand J Gastroenterol; 2011 Jul; 46(7-8):962-72. PubMed ID: 21623677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
    Tural C; Tor J; Sanvisens A; Pérez-Alvarez N; Martínez E; Ojanguren I; García-Samaniego J; Rockstroh J; Barluenga E; Muga R; Planas R; Sirera G; Rey-Joly C; Clotet B
    Clin Gastroenterol Hepatol; 2009 Mar; 7(3):339-45. PubMed ID: 19171202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Ratziu V; Massard J; Charlotte F; Messous D; Imbert-Bismut F; Bonyhay L; Tahiri M; Munteanu M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; Poynard T; ;
    BMC Gastroenterol; 2006 Feb; 6():6. PubMed ID: 16503961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
    Beckebaum S; Iacob S; Klein CG; Dechêne A; Varghese J; Baba HA; Sotiropoulos GC; Paul A; Gerken G; Cicinnati VR
    Transplantation; 2010 Apr; 89(8):983-93. PubMed ID: 20335832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
    Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
    Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
    Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.
    Calès P; Boursier J; Chaigneau J; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Cavaro-Ménard C; Gallois Y; Deugnier Y; Rousselet MC
    Liver Int; 2010 Oct; 30(9):1346-54. PubMed ID: 20666992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
    Boursier J; Vergniol J; Sawadogo A; Dakka T; Michalak S; Gallois Y; Le Tallec V; Oberti F; Fouchard-Hubert I; Dib N; Rousselet MC; Konaté A; Amrani N; de Ledinghen V; Calès P
    Liver Int; 2009 Nov; 29(10):1507-15. PubMed ID: 19725892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting.
    Lesmana CR; Salim S; Hasan I; Sulaiman AS; Gani RA; Pakasi LS; Lesmana LA; Krisnuhoni E; Budihusodo U
    J Clin Pathol; 2011 Oct; 64(10):916-20. PubMed ID: 21670074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Subasi CF; Aykut UE; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):137-41. PubMed ID: 25486027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
    Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
    J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
    Snyder N; Nguyen A; Gajula L; Soloway R; Xiao SY; Lau DT; Petersen J
    Clin Chim Acta; 2007 Jun; 381(2):119-23. PubMed ID: 17442291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B].
    Tu XL; Xiao YQ; Chen F
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):28-32. PubMed ID: 19203448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index.
    Petta S; Di Marco V; Cammà C; Butera G; Cabibi D; Craxì A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1350-60. PubMed ID: 21517924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection.
    Carvalho-Filho RJ; Schiavon LL; Narciso-Schiavon JL; Sampaio JP; Lanzoni VP; Ferraz ML; Silva AE
    Liver Int; 2008 Apr; 28(4):486-93. PubMed ID: 18339075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.